NOVO NORDISK INC.: Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy in a pill*) and obesity pipeline at ObesityWeek 2025

New data from OASIS 4 on oral semaglutide 25 mg to reveal insights on cardiometabolic health among adults with obesity or overweight Additional trial insights ...
FoodNavigator

How big is the GLP-1 wave going to get, really?

GLP-1 drugs like Ozempic and Wegovy are transforming public health and consumer habits. Here we explore their explosive ...
New Atlas

First oral GLP-1 cuts cardiovascular risk by 14% – and it's now FDA-approved

The age of the GLP-1 drug has reached yet another milestone, with the US Food and Drug Administration green-lighting Novo Nordisk's once-daily oral semaglutide pill to treat people at high risk of ...